Ayash-Rashkovsky Mila, Borkow Gadi, Davis Heather L, Moss Ronald B, Bartholomew Richard, Bentwich Zvi
Hebrew University Hadassah Medical School, Jerusalem, Israel.
FASEB J. 2005 Jul;19(9):1152-4. doi: 10.1096/fj.04-3185fje. Epub 2005 Apr 15.
We have recently developed a novel small animal model for HIV-1 infection (Ayash-Rashkovsky et al., http://www.fasebj.org/cgi/doi/10.1096/fj.04-3184fje; doi:10.1096/fj.04-3184fje). The mice were successfully infected with HIV-1 for 4-6 wk with different clades of either T- or M-tropic isolates. HIV-1 infection was accompanied by rapid loss of human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation. HIV specific human humoral and cellular immune responses were observed in all HIV-1 infected animals. In the present study, HIV specific human immune responses, both humoral and cellular, were generated in noninfected Trimera mice, after their immunization with gp120-depleted HIV-1 antigen, presented by autologous human dendritic cells. Addition of CpG ODN to the antigen-pulsed DCs significantly enhanced (by 2- to 30-fold) the humoral and cellular HIV-1 specific immune responses. Only mice immunized with the HIV-1 immunogen and CpG were completely protected from infection with HIV-1 after challenge with high infection titers of the virus. This novel small animal model for HIV-1 infection may thus serve as an attractive platform for rapid testing of candidate HIV-1 vaccines and of adjuvants and may shorten the time needed for the development and final assessment of protective HIV-1 vaccines in human trials.
我们最近开发了一种新型的HIV-1感染小动物模型(阿亚什-拉什科夫斯基等人,http://www.fasebj.org/cgi/doi/10.1096/fj.04-3184fje;doi:10.1096/fj.04-3184fje)。用不同分支的T嗜性或M嗜性分离株成功感染小鼠4至6周。HIV-1感染伴随着人CD4+T细胞的迅速减少、CD4/CD8比值的降低以及T细胞活化的增加。在所有感染HIV-1的动物中均观察到了HIV特异性的人体液免疫和细胞免疫反应。在本研究中,未感染的三联体小鼠在用gp120缺失的HIV-1抗原免疫后,由自体人树突状细胞呈递,产生了HIV特异性的人免疫反应,包括体液免疫和细胞免疫。向抗原脉冲的树突状细胞中添加CpG ODN可显著增强(2至30倍)体液和细胞HIV-1特异性免疫反应。只有用HIV-1免疫原和CpG免疫的小鼠在受到高感染滴度病毒攻击后才完全受到保护,免于感染HIV-1。因此,这种新型的HIV-1感染小动物模型可能成为快速测试候选HIV-1疫苗和佐剂的有吸引力的平台,并可能缩短在人体试验中开发和最终评估保护性HIV-1疫苗所需的时间。